Eloxx Pharmaceuticals, Inc. (ELOX)

NASDAQ: ELOX · IEX Real-Time Price · USD
0.330
+0.056 (20.22%)
Aug 12, 2022 10:53 AM EDT - Market open
20.22%
Market Cap 28.60M
Revenue (ttm) n/a
Net Income (ttm) -69.65M
Shares Out 86.65M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 270,376
Open 0.260
Previous Close 0.275
Day's Range 0.260 - 0.330
52-Week Range 0.210 - 1.890
Beta 2.18
Analysts Buy
Price Target 2.04 (+518.2%)
Earnings Date Aug 15, 2022

About ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysi... [Read more...]

Industry Pharmaceuticals
Founded 2013
CEO Gregory Williams
Employees 28
Stock Exchange NASDAQ
Ticker Symbol ELOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 518.18% from the latest price.

Price Target
$2.04
(518.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

Cystic Fibrosis Foundation (CF Foundation) to provide an a ward of up to $ 15.9 million for the ongoing ELX-02 clinical program

Read Why Eloxx Pharma Stock Continues To Fall

H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) to $1 from $2 and reiterated a Neutral rating. Analyst Andrew Fein says the ELX-02 top-line data "raises more questio...

Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) posted topline results from the monotherapy arms of its Phase 2 trial of ELX-02 in Class 1 cystic fibrosis patients with at least one G542X nonsense allele mutat...

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in C...

ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity

Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021

Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights

Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Cap...

Eloxx Stock Moves Higher On Fast Track Tag For Cystic Fibrosis Candidate

The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's (NASDAQ: ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in ...

New Strong Sell Stocks for August 24th

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Other symbols: BGSFTHMNTLA

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)

Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer

Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LON...

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021

Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?

Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?

Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.

Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwrit...

WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the c...

Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday

Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...

Other symbols: BNGOCRMD

Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the p...

Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies

Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor)

Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?

Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Eloxx Stock is Trading Higher After Zikani Therapeutics Acquisition

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare disease...